Discussion: The QSP platform predicts strong and complex genotypedependent interactions with aripiprazole, risperidone, haloperidol and paliperidone and to a much smaller degree with olanzapine, quetiapine and clozapine. These predictions could in principle be verified in clinical setting and could lead to rational personalized treatment guidance An earlier age of onset negates the protective effects of more mature psychosocial and individual variables, thus the potential for worse outcomes. Genetic variations in this relationship are important to understand as this will allow not only a better understanding of the biological interaction of cannabis and psychosis, but would inform future genetic approaches to risk identification as well. We uniquely examined the mediation of this association (gene x cannabis associations in age of onset of psychosis (AoP)) in 3 genetic variants which, while each have been examined separately, not in combination in the same population. We examined: 1) COMT Val158Met (rs4680) 2) BDNF Val66Met (rs6265) and 3) the AKT1 variant rs2494732. Methods: 168 subjects with a diagnosis of psychosis were recruited from 2 sites in Canada, Edmonton Alberta and Halifax Nova Scotia. Cannabis use data (age at first and regular use) were collected using an electronic self-report survey (to address potential minimization of use to a researcher) and saliva samples were used for genotyping. Kaplan-Meier and Cox regression analyses were used to study the gene -cannabis effects.
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Background: Treatment with antipsychotics can provoke drug-related movement disorders (DRMD) (also known as extrapyramidal symptoms (EPS)), i.e. tardive dyskinesia (TD), parkinsonism, akathisia and tardive dystonia. DRMD remain a cause for concern in the treatment of patients with psychotic disorders, especially because the DRMD can become irreversible (Correll and Schenk, 2008) . There are lower percentages in younger patients (32%) (Mentzel 2017) , but the prevalence is substantial in chronic patients (68%) (Bakker 2011), with around a quarter of chronic patients showing two different types of DRMD (Bakker 2011). DRMD can cause severe impairment in quality of life (Fujimaki 2012. In addition, a meta-analysis (Ballesteros 2000) and two recent studies showed a higher mortality in patients with tardive dyskinesia (Chong 2009, Dean and Thuras 2009) . It is therefore important to find ways of preventing DRMD. Pharmacogenetic studies may identify genetic risk factors, which underlie individual vulnerability for DRMD in response to antipsychotics (Reynolds 2007; Ohmori 2003; Lerer 2002) , in theory paving the way for individually tailored medication prescriptions (Lerer and Segman 2006). To date, many different papers have been written on the subject and they have presented inconsistent results. The aim of this umbrella review is to provide clinicians and patients with evidence-based information regarding the genes that are thought to be associated with DRMD and to use this umbrella review on the genetics of DRMD as a basis for recommendations for future prevention programs and research. Methods: To identify all relevant meta-analyses a Medline, Embase, and Psychinfo literature search was performed. Titles and abstract were screened using predetermined criteria by two independent authors. The methodological quality of included meta-analyses was assessed by two overview authors using 'assessment of multiple systematic reviews' (AMSTAR) critical appraisal checklist. Reference lists of included papers and those of reviews were cross-checked and no new publications were found. Results: The search yielded 14 meta-analysis studies and consensus was obtained. The DRD3, DRD2, CYP2D6, 5-HT2A, COMT and MnSOD genes all contain variants that increase the odds ratio of TD. However meta-analyses showed diminishing significance over time and meta-analyses on the same subject were difficult to compare due to differences in patient population and methods used. Discussion: For now it appears that TD is a complex disease with multiple genes that are involved in its phenotype and more studies (eg. Genome wide associatio studies), on a larger scale, are required to develop a genetic test kit to predict the chance of TD. To achieve this multiple research groups need to work together, a DRMD genetic database needs to be in place to overcome publication bias and results need to be stratified by patient characteristics. The result could be test that undoubtedly will be of great clinical value in treating patients and by prospectively preventing debilitating DRMD. Background: Schizophrenia is a highly heritable psychiatric disorder. In the past 30 years, thousands of case-control and family-designed association studies have examined candidate genes for schizophrenia. To assist the field in interpreting this large volume of gene-association studies, the online SzGene database was created and included meta analyses for 287 polymorphisms at the time of its final update in 2010. However, since then more than one-thousand new gene-association studies in schizophrenia have been conducted. As such, we have conducted an updated systematic review and meta-analysis of all gene-association studies in schizophrenia published before March 2017. Methods: Studies published between January 2010 and March 2017 were identified using a customized querying strategy. Identified gene-association studies were included in the review and meta-analysis if they: 1) were casecontrol or family-designed studies with polymorphisms detected in schizophrenia or schizoaffective patients, 2) provide sufficient data to perform meta-analysis, and 3) were not genome-wide association studies (GWAS). Random-effects meta-analysis was performed on polymorphisms with four or more independent studies. Results: Raw data of 1711 studies included in the SzGene database were integrated with 1368 studies identified from our systematic literature search. Random-effects meta-analysis were applied to 540 polymorphisms with at least four studies and 89 of these polymorphisms were nominally associated with SZ (unadjusted p < 0.05). After bonferroni correction, 12 polymorphisms remained statistically significant, including five associations not reported in the most recent Psychiatric Genomics Consortium schizophrenia GWAS: 1) rs11098403, p = 1.45e-10, odds ratio = 0.65; 2) rs12807809, p = 7.04e-06, odds ratio = 0.91; 3) rs910694 in PDE4B: p = 1.05e-05, odds ratio = 0.77; 4) rs1801133 in MTHFR: p = 2.99e-05, odds ratio = 1.13 and 5) rs1602565: p = 7.73e-05, odds ratio = 1.11. Discussion: Our results provide a comprehensive and up-to-date review of candidate gene association studies in schizophrenia. Findings complement results from GWASs in schizophrenia but also expand the current list of candidate loci for schizophrenia. Background: Retinoic acid (RA) is intrinsically linked to neurodevelopment and has been implicated in schizophrenia (SZ). This is supported by preliminary trials of a retinoid receptor agonist, Bexarotene, as an adjuvant and the association of five common variants in proximity to members of this pathway at genome wide significance. In addition to these high frequency variants with small effect size, we suspect that this pathway is also affected by rare variants with much higher impact. We aimed to examine the burden of variants in retinoid loci in schizophrenia along with its potential consequences for clinical practice. Methods: Whole genome sequencing was performed on SZ cases (N=331) and non-psychiatric controls (N=167). Cases were further clustered by cognitive measures to derive the cognitive deficit (CD; N=166) and cognitively spared (CS; N=165) subtypes. Disease and subtype associated genomic variation was then analysed in a panel of 129 genes selected for involvement in RA biology (Molecular Signatures Database). Rare variation was aggregated at the gene level using the optimal unified sequence kernel association test (SKAT-O). Clinical metadata was further examined for each case with a rare putative high impact loss of function variant in a RA panel gene predicted using SnpEff. The rare variant burden on target genes of RA receptor binding in SZ was investigated by logistic regression of variants mapped to consensus 5 base pair spaced direct repeat (DR5) retinoic acid response element (RARE) motifs. Results: Gene level rare variant association uncovered suggestive associations with SZ (P < 0.01) for three retinoid genes -RBP3, ADH1C and RPE65. In addition, a stronger signal was detected overall for CD cases implicating four additional genes including the RA receptors RARB (P = 1.1 x 10-3) and RARG (P = 9.2 x 10-3). SZ patients with a rare high impact genotype predicted in a RA panel gene were more likely to have serious symptomology as defined by a global assessment of functioning (GAF) score below 50, P = 7.1 x
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